Identification and binding mode of a novel *Leishmania* Trypanothione reductase inhibitor from high throughput screening

Lorenzo Turcano1, Esther Torrente1, Antonino Missineo1, Matteo Andreini1, Marina Gramiccia2, Trentina Di Muccio2, Ilaria Genovese3, Annarita Fiorillo3, Steven Harper1, Alberto Bresciani1, Gianni Colotti4*, Andrea Ilari4*

1 IRBM Science Park S.p.A. Via Pontina Km 30, 600–00071 Pomezia (RM), Italy, 2 Dipartimento di Malattie Infettive—Istituto Superiore di Sanità Viale Regina Elena, Roma, Italy, 3 Dipartimento di Scienze Biochimiche, “Sapienza” Università di Roma P.le A. Moro, Roma, Italy, 4 Istituto di Biologia e Patologia Molecolari–CNR, and Dipartimento di Scienze Biochimiche, “Sapienza” Università di Roma P.le A. Moro, Roma, Italy

* gianni.colotti@uniroma1.it (GC); andrea.ilari@uniroma1.it (AI)

Abstract

Trypanothione reductase (TR) is considered to be one of the best targets to find new drugs against Leishmaniasis. This enzyme is fundamental for parasite survival in the host since it reduces trypanothione, a molecule used by the tryparedoxin/tryparedoxin peroxidase system of *Leishmania* to neutralize hydrogen peroxide produced by host macrophages during infection. In order to identify new lead compounds against *Leishmania* we developed and validated a new luminescence-based high-throughput screening (HTS) assay that allowed us to screen a library of 120,000 compounds. We identified a novel chemical class of TR inhibitors, able to kill parasites with an IC₅₀ in the low micromolar range. The X-ray crystal structure of TR in complex with a compound from this class (compound 3) allowed the identification of its binding site in a pocket at the entrance of the NADPH binding site. Since the binding site of compound 3 identified by the X-ray structure is unique, and is not present in human homologs such as glutathione reductase (hGR), it represents a new target for drug discovery efforts.

Author summary

Human leishmaniasis is one of the most diffused neglected vector-borne diseases and causes 60,000 deaths annually, a rate surpassed only by malaria among parasitic diseases. Anti-*Leishmania* treatments are unsatisfactory in terms of their safety and efficacy and there is an urgent need to find treatments. Compounds targeting proteins that are essential for parasite survival but that are not present in the human host are of especial interest with a view to developing selective and non-toxic drugs. *Leishmania* uses trypanothione as its main detoxifying molecule, allowing the parasite to neutralize the reactive oxygen species produced by macrophages during the infection. Trypanothione is activated by
Trypanothione reductase (TR), an enzyme that is absent in man but that is essential for parasite survival, and is therefore considered an attractive target.

The new luminescence-based high-throughput screening assay that we have developed and validated allowed us to identify new TR inhibitors by screening a collection of 120,000 compounds. Hit follow-up led to a prototype molecule, compound 3, that we have shown is able to bind in a cavity at the entrance of the NADPH binding site, thereby inhibiting TR. Compound 3 is not able to inhibit the human homolog glutathione reductase (hGR) since the residues lining its NADPH binding cavity are not conserved with respect to TR. Based on their mechanism of action, compounds from the class represented by compound 3 are useful leads for the design new drugs against leishmaniasis.

Introduction

Protozoan parasites from the Leishmania genus are the causative agent of leishmaniasis, a neglected tropical disease that infects numerous mammals (including humans) throughout the world. Human leishmaniasis consists of three major clinical forms: visceral leishmaniasis (VL), which is fatal if left untreated; cutaneous leishmaniasis, which can heal spontaneously but leaves disfiguring scars; and mucocutaneous leishmaniasis, which is not self-healing and can potentially be fatal. VL is caused by Leishmania donovani in East Africa and the Indian subcontinent and by Leishmania infantum in Europe, North Africa, and Latin America. VL causes an estimated 60,000 deaths annually, a rate surpassed among parasitic diseases only by malaria.[1, 2] Leishmania spp., together with other protozoan pathogens responsible for diseases such as sleeping sickness (Trypanosoma brucei) and Chagas disease (Trypanosoma cruzi), belong to the Trypanosomatidae (trypanosomatids) family. The therapy of Trypanosomatidae, and in particular of VL, represents a neglected area of research and drug discovery/development. Currently, treatments for these diseases (e.g. antimony, amphotericin, paramomycin, miltefosine, aminoquinoline, sitamaquine) are unsatisfactory in terms of their safety and efficacy.[3] This sharply contrasts with the therapeutic need for VL treatments, number of affected patients, and associated fatalities. This discrepancy is primarily due to the distribution of these infections in neglected tropical and subtropical geographies that have inadequate research capacities and public-health infrastructures. Advances in the field of leishmaniasis drug discovery, recently reviewed by Zulfiqar and colleagues[4] suggest that new compounds targeting proteins essential for parasite survival but that are absent in the human host are attractive targets when demonstrated to be translatable in vivo.

In contrast to the mammalian redox defense machinery that is based on glutathione, trypanosomatid parasites possess trypanothione as the main detoxifying system against oxidative damage. Trypanothione [N1,N8-bis(glutathionyl)spermidine] (TS₂), which is synthesized by trypanothione synthetase (TryS) and reduced to T(SH)₂ by the trypanothione reductase (TR), is used by the couple tryparedoxin/tryparedoxin peroxidase I (TXN/TXNPx) to neutralize hydrogen peroxide produced by macrophages during infection (Fig 1).[5–7] All attempts to date to obtain a TR-null mutant in L. donovani have failed and mutants displaying a partial trisomy of TR locus, where two TR alleles are disrupted by gene targeting, show attenuated infectivity and decreased ability to survive within the macrophages.[8] TR is thus an attractive target for the development of potential new drugs against trypanosomatids since it is essential for parasite survival but is absent in the human host. The human homolog, glutathione reductase (hGR), that maintains glutathione in a reduced state, has a significantly different substrate
binding site in terms of both volume and charge distribution, suggesting the possibility of identifying molecules able to selectively target TR.[5]

The crystal structure of *L. infantum* TR[9] has been shown to be very similar to the structure of other trypanosomatid TRs solved to date such as those from *Crithidia fasciculata*, *T. cruzi* and *T. brucei*.[10–12] TR is a two-fold symmetrical homodimer in which each subunit is formed by three domains, the interface domain (residues 361–488), the NADPH binding domain (residues 161–288) and the FAD binding domain (residues 1–160 and 289–360). The trypanothione binding site resides in a large cavity at the interface between the two monomers, formed by the residues of the FAD binding domain of one sub-unit and those of the interface domain of the other. Reduction of trypanothione catalyzed by TR takes place by a mechanism in which two electrons are transferred from NADPH via FAD to the Cys52-Cys57 disulfide...
bridge. TS₂ then binds to the protein and Cys52, deprotonated by the couple His461’-Glu466’, nucleophilically attacks the trypanothione disulfide bridge resulting in formation of a mixed disulfide. Finally, the attack of Cys57 on Cys52 promotes the release of the reduced substrate.

Metals and metal-containing compounds can inhibit TR by binding to the active site,[13–16] and antimony-containing drugs that block TR activity are known.[9] In addition to such metal compounds that bind to the two active catalytic cysteines,[17] several organic compounds have also been shown to inhibit TR activity. Diaryl sulfide,[18, 19] 2-iminobenzimidazoles,[20] polyamine analogs,[21] quinoline-based compounds,[22] pyrimidopyridazine-based scaffolds,[22] azole-based compounds[23] and lunarine analogs[24] have all been reported. Some of these compounds were identified by high throughput screening (HTS) employing the colorimetric method for detection of TR activity [22, 25] developed by Hamilton et al.[26]

In the current work our studies aimed first at setting up a new assay in which NADPH oxidation was coupled to a luminescence assay. After optimization for screening, the assay was used in an HTS effort to identify new classes of compounds able to inhibit TR and to act against Leishmania parasites. For this purpose, we screened our in-house library containing 120,000 compounds and succeeded in identifying a novel hit series of L. infantum TR inhibitors. Compound 3, a representative compound from this new series of TR inhibitors, was shown by X-ray crystallography to bind at previously unknown but druggable site at the entrance of the NADPH binding cavity. Compounds from this class of TR inhibitors were shown to have activity against Leishmania parasites in a growth assay.

**Methods**

**Compound collection**

At the time the HTS was performed, a collection of approximately 120,000 small molecules from both commercial and non-commercial suppliers was available through the CNCCS public-private consortium (www.cnccs.it). In addition to FDA and/or EMA approved drugs the collection contained a structurally diverse range of chemotypes with average molecular weight 370 Daltons. The collection was constructed aiming for high internal structural diversity (average Tanimoto distance from the nearest neighbour of 0.38) [27] while maintaining an attractive distribution of physicochemical properties (e.g. calculated logD, sp3 character, hydrogen bond donor/acceptors and total polar surface area).

**Enzymatic assay**

*L. infantum* TR was cloned and purified as previously described.[9, 28] Bovine serum albumin (BSA), NADPH, auranofin, hGR, oxidized glutathione (GSSG) and DTNB were purchased from Sigma-Aldrich (St. Louis, MO); oxidized trypanothione (TS₂) was purchased from Bachem (Bubendorf, Switzerland); the NADPH-Glo kit was purchased from Promega (Madison, WI, U.S.A.). Compounds, dissolved in DMSO, were transferred to 384-well white plates (Greiner Bio One, Frickenhausen, Germany) using the acoustic droplet ejection technology (ATS-100, EDC Biosystems, U.S.A.) to reach the desired final concentration. The TR enzymatic reaction was performed by addition of 0.1 nM TR, 12.5 μM NADPH, 15 μM TS₂ in 50 mM HEPES (pH 7.4), 40 mM NaCl, 0.01% BSA in a final volume of 15 μL. After 60 min of incubation at room temperature, an equal volume of NADPH-Glo reagent was added and the luminescent signal was acquired by an EnVision plate reader (PerkinElmer, Waltham, MA, U.S.A.). In fact the NADPH-Glo signal was demonstrated to stabilize after 30 minute (S1 Fig) according to the reagent data sheet. In addition, in order to make sure that the production of a reducing agent (i.e. T(SH)₂) by the TR activity was not going to interfere with the assay, and in
absence of T(SH)₂ as purified reagent, the effect of DTT and GSH was tested on the NADPH--
Glo reaction resulting in no interference at concentrations relevant for the current setup (S2
Fig). The hGR assay was performed by addition of 0.5 nM hGR, 10 μM GSSG, 20 μM NADPH
in 50 mM HEPES (pH 7.4), 40 mM NaCl, 0.01% BSA in a final volume of 15 μL. After 30 min
incubation at room temperature 15 μL of NADPH-Glo kit was added to reveal the signal. The
5,5’-dithiobis(2-nitrobenzoic acid) (DTNB) assay was performed using 2 nM TR, 100 μM
NADPH, 4 μM TS₂ and 200 μM DTNB in 40 mM HEPES (pH 7.4), 1 mM EDTA, 0.01% BSA
and 0.05% tween-20 in a final volume of 50 μL. The absorbance signal (412 nm) was acquired
15 minutes post incubation at room temperature using the plate reader (Safari2, Tecan, Swit-
zeland). Results were analyzed using Prism software (GraphPad, San Diego, CA, U.S.A.)
and Vortex (Dotmatics, Bioshops Stortford, UK). Dose-response curves were fitted by four-param-
eter logistic regression.

Compound similarity search
After hit confirmation compound similarity searches were performed by generation of circular
Morgan fingerprints (radius 2, 2048 bits) for the test compounds using open source RDKit
software (http://www.rdkit.org/, release 2014_09_2). The molecular representations generated
were used to perform ligand based virtual screening against the target databases (i.e. our own
screening collection) that is described above or a subset of the public ZINC database (http://
zinc.docking.org) from which PAIN’s and undesirable structures were removed). Similarity
was assessed by the Tanimoto index between the reference and target structures using a cut-off
of 0.6. Similar compounds were clustered using Taylor-Butina clustering, a non-hierarchical
clustering method that ensures that each cluster contains molecules with a set cut-off (or
threshold) distance from a central compound.[29] Compounds selected for purchase or
screening follow up were chosen from the most populated clusters, with either the central
compound or a close analog (based on visual inspection) being used to represent the com-
pound cluster. All selected compounds were quality controlled by UPLC-MS prior to testing.

Competition assay
Competition assays were performed using three test concentrations (4, 16 and 64 μM) for the
competing compounds. The reaction buffer and components were mostly identical to those
used in the TR assay described above, but 1 nM TR was employed for 5 minutes against a serial
dilution of either TS₂ in presence of 40 μM NADPH or NADPH in presence of 30 μM TS₂.
The residual amount of NADPH was measured using the NADPH-Glo kit (Promega, U.S.A.)
after 30 min incubation at room temperature as per the manufacturer’s protocol. The lumines-
cent signal was measured using the EnVision plate reader (PerkinElmer, USA). IC₅₀, Vₘₐₓ, and Kₘ values were calculated using Prism software (GraphPad, San Diego, CA, U.S.A.).

Binding assay by SPR
Surface plasmon resonance (SPR) interaction analysis was performed using a Biacore T200
(GE Healthcare, Uppsala, Sweden). TR was immobilized on a CM4 chip by amine coupling
according to manufacturer’s instructions (Amine Coupling Kit, GE Healthcare, Uppsala, Swe-
den). Briefly, the surface of the sensor chip was activated for 7 min using a mixture of 0.1 M N-
hydroxy succinimide (NHS) and 0.4 M N-ethyl-N’-[3-dimethyl-aminopropyl] carbo-diimide
(EDC) then 25 μg/mL of TR in 10 mM sodium acetate (pH 5.0) was injected for 360 s at 10 μl/
min, finally residual activated groups on the surface were blocked by a 7-min injection of 1 M
ethanolamine (pH 8.5). A reference channel for background subtraction was prepared by activa-
tion with EDC/NHS mixture (0.1 M/0.4 M as per ligand immobilization), followed by
blocking with 1 M ethanolamine. The binding of the selected hit to the immobilized ligand was evaluated by a multi-cycle kinetic procedure in 50 mM HEPES pH 7.4, 40 mM NaCl, 0.05% Tween-20 supplemented with 2% DMSO (Sigma Aldrich). The analyte was injected for 20 s at 30 μl/min until equilibrium and dissociation monitored for 120 s. A standard curve of DMSO was included for solvent correction. Biomolecular binding events were reported as changes of resonance units (RUs) over time. The data were analysed by the Biacore T200 evaluation software: specific sensorgrams were obtained for the analyte, by subtracting the signals of the reference channel to those of the TR-immobilized one, and corrected for DMSO interference from DMSO standard curve. The binding affinity was evaluated at steady state whereas the kinetic parameters were calculated by a one-phase association and two-phase dissociation model using the Prism software (GraphPad, San Diego, CA, U.S.A.)

**X-ray structure determination**

*L. infantum* TR was cloned, purified and crystallized as previously reported.[9, 28] The crystals were obtained by the hanging drop vapor diffusion method at a temperature of 294 K, using as precipitating agent ammonium sulfate in a range between 1.4 and 1.7 M, in a Tris–HCl buffer at pH 8.0–8.7. The crystals reached a dimension of 0.3 mm x 0.3 mm x 0.2 mm in about 7 days. Crystals of the native oxidized TR were soaked for 2 h using a stabilizing solution containing 1.5 M ammonium sulfate, 0.1 M Tris pH 8.5 and 1 mM compound 3 (2-(diethylamino)ethyl-4-((3-(4-nitrophenyl)-3-oxopropyl)amino)benzotate). Crystals were cryo-protected in a solution of mother liquor 75% and glycerol (25%), then flash-frozen by quick submersion into liquid nitrogen for transport to a synchrotron radiation source.

Single wavelength data sets (λ = 1.073 Å) were collected at the beamline ID29 at the Synchrotron Radiation Source ESRF, Grenoble (France) using a Dectris Pilatus 6M-F detector at a temperature of 100 K. The data sets were processed and scaled with XDS,[30] The crystals belong to the P4,2,12 space group with the following cell dimensions: a = 103.33 Å, b = 103.33 Å, c = 191.55 Å. Crystal parameters and complete data collection statistics are reported in Table 1. The structure of *L. infantum* TR in complex with compound 3 was solved with the program Molrep [31] by molecular replacement using the native TR (PDB code: 2JK6) [9] as search model. Refinement was performed using the program REFMAC5[32] and model building was carried out using the program COOT.[33] The structure of TR in complex with compound 3 was refined to a final free R value of 20.6% for all resolution shells (73–3.37 Å), calculated using the working set reflections (14626), and Free R value, calculated using the test set reflections (737), of 26.5%. The final model is a monomer containing 488 residues, a FAD molecule, two sulfate molecules, and one compound 3 molecule. The most favored regions of the Ramachandran plot contain 90.0% of residues, the allowed regions contain 9.0% of residues, with 1% in disallowed region. The X-ray structure has been deposited in the protein data bank with the PDB (Protein Data Bank) code 6ER5.

**Inhibition of promastigote growth**

Promastigote (the extracellular stage of the *Leishmania* life cycle) growth inhibition was evaluated using *L. infantum* strain (MHOM/TN/80/IPT1). To estimate the 50% inhibitory concentration (IC₅₀), the MTT (3-[4.5-dimethylthiazol-2-yl]-2.5-diphenyltetrazolium bromide) micromethod[34] was used throughout the experiments with modification.[18] Promastigotes were grown in Schneider’s *Drosophila* medium (SIGMA) containing 10% Fetal Calf Serum (FCS) (GIBCO-BRL) and 2% gentamicin (50 mg/L) (Sigma) at 22°C. Parasites were adjusted to 1 × 10⁶ parasites/mL, and 200 μL of suspension was seeded in triplicate in 96-well flat bottom microplates and incubated with varying concentrations of compound. Amphotericin B
IC₅₀ (0.5 μM) (Euroclone) was used as control. Each experiment was done in triplicate for each drug concentration and two independent experiments were performed. After 72 h of incubation, 30 μL of MTT was added to each well and plates were further incubated for 2 h. The absorbance at 550 nm was measured with a 96-well scanner (DINEX Technologies, VA, USA). Anti-leishmanial activity per experimental point was expressed as mean percentage of inhibition with respect to vehicle treated parasites (0%). In addition, the promastigote vitality was followed by microscopic observation after 72 h. Data were analyzed and plotted by Prism (GraphPad, San Diego, USA).

### Chemistry

Compounds were obtained from commercial suppliers and were tested without further purification. Purity of final compounds were determined using mass spectrometry (MS) and ultra-high performance liquid chromatography (UPLC). UPLC-MS analyses were performed on a Waters Acquity UPLC, equipped with a diode array and a ZQ mass spectrometer, using a Waters BEH C18 column (1.7 mm, 2.1 x 50 mm). The mobile phase comprised a linear gradient of binary mixtures of H₂O containing 0.1% formic acid (A), and MeCN containing 0.1% formic acid (B). The following linear gradient was used (A): 90% (0.1 min), 90%-0% (2.6 min), 0% (0.3 min), 0%-90% (0.1 min). The flow rate was 0.5 mL/min. The purity of final

### Table 1. Crystal parameters, data collection statistics and refinement statistics of compound 3-TR complex.

| **Space group** | P4₁2₁2₁ |
|-----------------|----------|
| **Unit cell parameters** |          |
| a (Å)          | 103.33   |
| b (Å)          | 103.33   |
| c (Å)          | 191.55   |
| **Number of molecule in the asymmetric unit** | 1        |
| **Wilson plot B factor (Å²)** | 118.4    |
| **Data statistics** |          |
| **Resolution range** | 3.37–73.01 (3.37–3.45) |
| **Unique reflections** | 15365 (1114) |
| **Completeness** | 99.9 (99.6) |
| **Redundancy** | 25.38 (26.29) |
| **CC1/2** | 99.9 (94.2) |
| **I/σ(I)** | 16.4 (2.4) |
| **Structure Refinement** |          |
| **Resolution range** | 3.37–73.01 (3.37–3.45) |
| **Reflection in bins** | 14626 (1045) |
| **R_ω_p (%)** | 20.6 (41.1) |
| **R_m_h (%)** | 26.5 (37.9) |
| **Rms bonds (Å)** | 0.008 |
| **Rms angle (°)** | 1.424 |
| **RSCC (for the compound 3)** | 0.58 |
| **Ramachandran plot** |          |
| **Residues in core region (%)** | 90 |
| **Residues in allowed region (%)** | 9 |
| **Residues in generously allowed region (%)** | 1 |

Values in parentheses are for the highest-resolution shell.

https://doi.org/10.1371/journal.pntd.0006969.t001
compounds was in all cases ≥95%. ¹H NMR spectra were recorded on Bruker AV400 spectrometer operating at 400 MHz. Chemical shifts (δ) are reported in parts per million downfield from TMS and are determined using the residual (undeuterated) NMR solvent peak as an internal standard.

2-(Diethylamino)ethyl 4-((3-(4-nitrophenyl)-3-oxopropyl)amino)benzoate (3). Compound 3 was purchased as a white solid from TimTec., ¹H NMR (400 MHz, DMSO- d₆, 294 K) δ 8.51 (2H, d, J = 8.4 Hz), 8.36 (2H, d, J = 8.4 Hz), 7.85 (2H, d, J = 8.0 Hz), 6.76 (2H, d, J = 8.0 Hz), 6.73 (1H, t, J = 6.7 Hz), 4.36 (2H, t, J = 6.0 Hz), 3.61–3.40 (4H, m), 2.91–2.85 (2H, m), 2.73–2.62 (4H, m), 1.12 (6H, t, J = 7.1 Hz); UPLC tᵣ 1.23 min (peak area 96%); MS (ES⁺) 414; (M +H)⁺; m.p. 128˚C.

**Results**

**TR assay development and optimization**

Purified *Leishmania infantum* TR was used to develop a new homogeneous bioluminescent assay in which a luminescence signal is coupled to the activity of TR by reaction with the residual NADPH after reduction of TS₂ (Fig 2A). This assay was miniaturized to a 384-well plate format for use in an HTS campaign. The design of the TR assay, which produces a positive signal in presence of a TR inhibitor, reduces the identification of false positives capable of interfering with luciferase activity. The linear range of the NADPH-Glo assay was established by serial dilution of NADPH, with a linear correlation between NADPH concentration and luminescent signal being appreciable up to 50 μM NADPH (Fig 2B). In order to optimize the substrate concentration to be used in the assay, the Kₘ of TS₂ for TR was determined by titrating its saturating concentration in the presence of 0.5 nM TR and 12.5 μM NADPH. The Vₐₚ for each TS₂ concentration was determined during the first 5 min of reaction and plotted against the TS₂ concentrations. When the curve was fitted by the Michaelis-Menten equation (Fig 3A) the TS₂ Kₘ (apparent) was found to be 13.5 ± 3.8 μM that was of the same order of magnitude of that measured by Angiulli and co-workers (Kₘ = 23 ± 1 μM).[35] To confirm this value, the Kₘ (apparent) of TS₂ was determined also by the standard 5,5′-dithiobis(2-nitrobenzoic acid) (DTNB) absorbance based assay using 20 nM TR and 100 μM NADPH. The TS₂ Kₘ (apparent) was found to be 3.6 ± 0.5 μM, in line with the result established by the new luminescence

---

![Fig 2](https://doi.org/10.1371/journal.pntd.0006969.g002)
approach. (Fig 3B). The concentration of NADPH used for further development of the luminescent assay was 12.5 μM since this value lies in the middle of the NADPH detection linearity range. Finally, an enzymatic reaction time course was carried out at four different concentrations of TR, ranging from 50 to 500 pM, keeping the TS₂ and the NADPH concentrations constant (at 15 μM and 12.5 μM respectively). The aim of this optimization step was to identify the appropriate enzyme concentration and incubation time needed to reach a compromise with respect to (1) having the lowest possible enzyme concentration to maximize assay sensitivity, (2) identifying a time point at which a clear signal is detected over the background to minimize potential experimental variability (3) allowing a reasonable time to assemble the reaction when hundreds of microplates need to be tested and (4) ensuring that the rate of the substrate consumption is reasonably away from the reaction completion (i.e. a linear trend is appreciable between signal and time). A concentration of 100 pM TR and 60 min incubation, despite pushing the boundaries of linearity, was identified as the acceptable compromise among enzyme concentration, signal robustness and assay duration (Fig 3C) at room temperature. The known TR inhibitor Auranofin (AF) [15] was used to benchmark the luminescent assay’s performance with respect to the standard DTNB readout. When tested in a dose-response manner in each assay, AF’s potency was 6.6 ± 1.05 μM and 154.5 ± 10.7 nM respectively on the luminescent and DTNB assays (Fig 3D). This difference may be related to the known propensity of AF to form adducts with thiol bearing compounds[36] and, as a consequence, to interfere with the
DTNB readout which is based on the reaction with free thiol moieties. To support to this hypothesis, a serial-dilution of AF was incubated with TR before and after the reaction took place. The signal was then developed by the addition of DTNB. The addition of AF, after the TR reaction was stopped, resulted in a dose-dependent decrease of the signal suggesting that AF does indeed at least partially interfere with the detection (S3 Fig).

Hit identification

The stability of the TR enzyme, NADPH and TS₂, working solutions at + 4°C and the NADPH-Glo at room temperature was tested in a time course fashion. The Z’ values [37], calculated between the no-enzyme condition and the full reaction were found to be greater than 0.5 up to 4 hours (Fig 4A) confirming that the assay is reliable within this time frame. As a consequence, the size of a single batch of assay plates was set in order not to exceed 4 h of total operation time. A collection of around 120,000 compounds was then screened at a fixed concentration of 10 μM using the above-described TR inhibition assay. The Z’ values of all the tested plates were found to be greater than 0.5, with an average of 0.79 (Fig 4B). The activity of each compound was calculated as Z-score (i.e. each compound value subtracted of the whole sample average and divided by the whole sample standard deviation). The distribution of the compound activities was found to be Gaussian (Fig 4C); as a consequence, compounds with activity equal to or greater than three standard deviations were considered hits (i.e. compounds whose chance to be false positive is statistically less than 0.3%). 290 compounds (0.23% of the total) were identified as active in the primary screening and subjected to confirmation assays.

Hit confirmation

In order to confirm hit compounds, dose-response curves were generated for active hits in the enzymatic assay using a starting concentration of 85 μM. TR inhibition activity was confirmed for 64 of the 290 hits identified in the primary screen with IC₅₀ potencies ranging from 2 to 35 μM. As previously reported, the design of the primary assay which produces a positive luciferase signal in the presence of an inhibitor meant that no luciferase inhibition counter-screen was necessary. The 64 compounds were further prioritized into three groups: i) 22 compounds that generated curves with a slope close to 1 and that reached 100% maximum inhibition; ii) 14 compounds with slope values between 1 and 2.5 and approximately 100% maximum inhibition; iii) 28 compounds with slope close to 1 and maximum inhibition values lower than 100%. Group ii) and iii) were deprioritized due to suboptimal biochemical inhibition. From

![Fig 4.](https://doi.org/10.1371/journal.pntd.0006969.g004)
the first of these groups (group i), removal of compounds with molecular weight > 600 Da-
tons or by visual structural inspection, reduced the number of compounds to 15. The activity
of second batches for all of these analogs was confirmed following the purchase or chemical
synthesis of fresh powders. In structural terms these compounds, which were viewed as the
most reliable results from the HTS effort, fell for the most part into two broad classes. Firstly,
several compounds containing an aryl N-acylhydrazone sub-structure (such as compound 1,
Fig 5) were found and interestingly were conceptually similar in structure to known TR inhibi-
tors.[23] Although compounds such as 1 showed low micromolar activity against TR they
were deprioritized at this stage based on their sub-optimal structures for drug development. A
small number of hits containing a 3-amino-1-arylpropan-1-one substructure (exemplified by
compounds 2 and 3 in Fig 5) were also found. These compounds were somewhat weaker in
terms of their TR inhibition (activity in the 10–30 μM range) but were judged more suitable
for follow-up. The testing of analogs around this hit series was performed with compounds
being selected either from the original screening collection (potential false negatives) or
through the purchase of structurally similar analogs. The selection of commercially available
analogs from the ZINC database was based initially on the presence of the required substructure
and analogs were clustered based on Tanimoto similarity (threshold 0.6) using circular
fingerprints. Selected analogs (about 40 compounds) were tested against TR and their specific-
ity with respect to human glutathione reductase (hGR) inhibition was also determined. The
hGR assay was performed using the same approach as the TR assay (see methods section). The
results from this follow up are summarized (for active analogs only) in S1 Table. Interestingly,
while compound 2 (one of the most active of the original hits) was not selective against hGR,
follow up compounds showed a clear trend toward selective behaviour (hGR IC_{50} values were
typically above 85μM). Although this follow up did not lead to strongly improved activity, the
confirmation of around 25% of the selected analogs as micromolar inhibitors of TR with weak
potency on hGR provided a level of comfort that these data were not false positive in nature.
Based on their low molecular weight and relatively simple and tractable chemical structures
compounds from the hit series were further profiled, and their interaction with TR was investi-
gated using compound 3 (Fig 5) as a representative of the class. The choice of compound 3 (S4
Fig) over other hits based on the 3-amino-1-arylpropan-1-one substructure (S1 Table) was
based on it having acceptable in vitro potency (7.5 ± 2.5 μM, S5 Fig) that was confirmed by the
DTNB assay, its high solubility (> 100 μM in assay buffer), and its relative structural complex-
ity with respect to its analogs. The presence of a nitro group as an undesirable structural fea-
ture in 3 was mitigated by structure activity relationship data from our hit confirmation work
(e.g. compounds 2, 6, 7 and 9, S1 Table, supplementary information) that suggests that the
nitro group is not a key pharmacophore element.

Fig 5. General structures of the two major hit series (substructures). Representative molecules for both series with TR inhibition potency data (examples).
Hit compound binding to TR

Binding of compound 3 to TR was initially evaluated by surface plasmon resonance (SPR). TR was covalently immobilized at high density (7,000 ΔRU) to a CM4 sensor chip, then the compound was injected over the surface at different concentrations, ranging from 6.25 to 50 μM. Although immobilization slightly affected the quote of active protein on chip (% TR<sub>max</sub> = 18%), a reliable binding signal was achieved. The sensorgrams were best fitted with a one-phase association and two-phase dissociation model which allowed to calculate the binding kinetic parameters (k<sub>on</sub>, k<sub>fast</sub> and k<sub>slow</sub>). Compound 3 was found to show fast on/fast off kinetics with a k<sub>on</sub> of 3.51 ± 1.09 x 10<sup>3</sup> (1/M·s), a k<sub>fast</sub> of 5.88 ± 0.96 (1/s) and a k<sub>slow</sub> of 0.08 ± 0.02 (1/s). The steady state calculated K<sub>d</sub> resulted to be 28.25 ± 5.12 μM in line with the compound’s potency in the luciferase screening assay (Fig 6). The reported suboptimal binding kinetics are expected for a hit compound. The two phase dissociation kinetics suggest that at least part of the binding is not driven by the two molecule complementarity. Likely the k<sub>slow</sub> is more predictive of the molecular interaction, in fact when the k<sub>slow</sub>/k<sub>on</sub> ratio is calculated, the obtained K<sub>d</sub> (22.7 μM) results in line with the steady state one.

Compound 3 was examined to determine whether or not it was competitive with either TS<sub>2</sub> or NADPH. The activity of the TR enzyme was assayed in the presence of alternate saturating dilutions of either TS<sub>2</sub> or NADPH and 4, 16 or 64 μM compound 3 (DMSO was used and negative control). The NADPH concentration for the TS<sub>2</sub> dilutions was 40 μM while the TS<sub>2</sub> concentration for the NADPH dilutions was 30 μM. Compound 3 was found be competitive for NADPH with apparent K<sub>m</sub> shifting to the right at increasing compound concentrations. Instead, compound 3 did not alter TS<sub>2</sub> K<sub>m</sub> whereas it affected TS<sub>2</sub> kinetics in terms of reaction V<sub>max</sub> (Fig 7).

X-ray crystal structure of TR in complex with compound 3

In order to study the mechanism of inhibition exerted by compound 3 ((2-(diethylamino) ethyl 4-((3-(4-nitrophenyl)-3-oxopropyl)amino)benzoate)) on TR and identify the binding
site of the compound X-ray crystallography studies were performed. We solved the X-ray structure of *L. infantum* TR in its oxidized state in complex with compound 3 (LiTR-3) at 3.37 Å resolution (Fig 8). The X-ray structure of the LiTR-compound 3 complex is homo-dimeric and is closely related to the TR-oxidized apo-form (Fig 8A).

The Fo-Fc map calculated using the dataset collected at ESRF and contoured at 3σ allowed identification of the binding site of compound 3 (Fig 8B). The low resolution structure and the poor quality map does not allow us to identify unequivocally the interaction of the ligand with the protein residues. However the Fo-Fc electron density map, allow the identification of the space occupied by the ligand and the residues involved in the binding even if the nitrophenyl group is not completely visible in the structure. In particular, as shown in Fig 8C, compound 3 is bound to the NADPH cavity entrance with an occupancy of 0.8, where it may form several mild electrostatic interactions with the protein residues lining its binding site. An electronic density peak was found close to Gly197, that has been interpreted as belonging to a sulfate ion (with 0.5 occupancy), which establishes electrostatic interactions with Gly197 and compound 3.

As shown in Fig 8C, compound 3 is lined by Tyr221, Gly197, Asn254, Arg222 and Arg228 a residue which is electrostatically bound to Arg235 (NH1(Arg235)-NH2(Arg228) distance = 3.5 Å).

The binding of compound 3 to the protein causes a local conformational change involving Arg228 and Arg222. Indeed, the superimposition between TR in oxidized state and the compound 3-TR complex shows that Arg228 and Arg222 undergo a 30° rotation (clockwise and anticlockwise, respectively) to allow compound binding (Fig 9A). As shown in Fig 9B, the comparison between the reduced TR (PDB code 2W0H) and the compound 3-TR complex shows that the inhibitor is placed at the entrance of the NADPH binding site. In particular, the nitro-phenyl group maps to the position of the adenine ring in the NADPH bound TR, and the two arginine residues (Arg222 and Arg228) that in the reduced enzyme interact with the adenine ribose phosphate moiety adopts a completely different conformation in the compound 3-TR complex (Figs 9B and S6).

The site is unique, since it is present in TR but not in the human homologs hGR and TrxR1.
As shown by the structural analysis (Fig 9C), residues Tyr221 and Asn254, which are involved in ligand binding to TR, are not conserved in hGR, where they are replaced by Ile217 and Gln250, respectively. Moreover, residues Gly229 and Arg235, important for the plasticity of the site as well as the correct positioning of the substrate in the site, are substituted in hGR by residues Ser225 and Ser231. Finally, residue Gly223 is substituted in hGR by the residue His219, which changes the charge and the steric hindrance of the binding site (Fig 9C).
Fig 9. (A) Superimposition between compound 3-TR complex and the apo TR (PDB code: 2JK6) structures. The structure of apo TR is colored blue, the compound 3-TR complex is colored magenta. The residues involved in the ligand binding are indicated and represented as sticks. (B) Superimposition between compound 3-TR complex (in magenta) and the reduced TR in complex with NADPH (in green) (PDB code: 2W0H). The two Arginine residues (Arg222 and Arg228) involved in the ligand binding are indicated and depicted as sticks. Compound 3 and NADPH are depicted as sticks and colored in light blue and green respectively. (C) Superimposition between compound 3-TR complex (in magenta) and Glutathione reductase (in yellow) (PDB code: 3GRS). The residues involved in the ligand binding are indicated (the residues of the compound 3-TR complex on the left side and the residues of GR on the right side) and depicted as sticks. The picture was obtained using PyMOL (The PyMOL Molecular Graphics System, Version 2.0 Schrödinger, LLC).

https://doi.org/10.1371/journal.pntd.0006969.g009
residues lining the compound-3 binding site are not even conserved in TrxTR1; indeed the residues Arg235, Tyr221, Gly223, Gly197, Asn254 are substituted by Ala233, Val220, Ser222, Ser199, Val252 in TrxTR1 (S7 Fig).

The structure of the compound-3-TR complex allows the identification of a new unique druggable site on TR which impedes the entrance of NADPH in the protein, thereby impairing trypanothione reduction. Up to now, structures of inhibitor-TR complexes have shown binding of inhibitors to the trypanothione binding site. Persch et al.[38] have solved the structure of TcTR and TbTR in complex with 5-[(5-[(1-(pyrrolidin-1-yl)cyclohexyl)]-1,3-thiazol-2-yl)][1H-indole (PDB codes: 4NEW and 4NEV); Fairlamb et al. [12] solved the X-ray crystal structure of TcTR in complex with Quinacrine mustard (N,N-{((1S)-4-{[(bis-(2-chloroethyl)amino)]}-1-methylbutyl})]-N-(6-chloro-2-methoxy-9-acridinyl)amine (PDB code: 1GXF); Patterson and coworkers [11] solved the X-ray structure of TbTR in complex with dihydroquinazolines inhibitors (PDB codes: 2WOI, 2WOV, 2WOW, 2WP5, 2WP6, 2WPC, 2WPE, 2WPF). The two structures of TR from Leishmania in complex with inhibitors present in the PDB show binding to L. infantum (Li) TR of a diarylpirrole-based inhibitor (PDB code: 4APN)[23] and of 6-(sec-butoxy)-2-((3-chlorophenyl)thio)pyrimidin-4-amine (RDS777) (PDB code: 5EBK)[18].

Activity against Leishmania infantum promastigote assays

Compound 3 induced a dose-dependent anti-proliferative effect on L. infantum promastigotes. Seventy-two hours after treatment, it induced 100% promastigote mortality up to 100 μM, whereas lower drug concentrations induced a dose-dependent anti-proliferative effect on L. infantum promastigotes. Compound 3 showed IC₅₀ of 12.44 ± 1.09 μM [95% CI: 10.20–32.64 μM] (Fig 10).

Discussion

The goal of this work was the identification of Leishmania TR inhibitors by HTS of a collection of over 100K small molecules. A new luminescence-based TR activity assay was developed in order to allow for robust and reliable testing. The assay was optimized for TS₂ and NADPH concentrations before it was used to screen the entire collection of 120,000 compounds. The
screening effort led to the identification of several hit molecules from which one series was selected for follow-up due to the presence of analogs with activity in the micromolar range together with structures judged suitable for further optimization. The prototype compound 3 was fully characterized with respect to its binding and competition with the TR substrate or cofactor and was found to be a reversible and NADPH competitive inhibitor. The low-resolution X-ray structure of the LiTR-compound 3 complex allowed us to identify the binding site of compound 3 (Fig 8B). Although the ligand is not completely visible in the structure, the structural information was sufficient to allow us to identify a new ligand binding site in TR that is not conserved in the human homologs hGR and hTrxR1.

As shown in Fig 9B, compound 3 is bound to the NADPH cavity entrance forming several weak electrostatic interactions with the protein residues lining its binding site, namely Arg228, Gly197, Tyr221, Asn254 and Arg222 (Fig 8C), thereby impeding the entrance of the substrate in the binding site. The ligand binding causes a significant displacement of the two arginine residues (Arg 222 and Arg 228) that in the NADPH bound TR are involved in the binding of the adenine ribose phosphate moiety (Figs 9B and S6). This result explains the competition between compound 3 and NADPH observed biochemically.

The binding of compound 3 to the protein causes a local conformational change involving Arg228 and Arg222 as shown in Fig 9A. This local conformational change induced by inhibitor binding may account for the presence of a biphasic dissociation phase, as shown by SPR assays.

The compound 3 binding site identified by the X-ray structure is unique, since it is present in TR but not in the human homologs hGR and hTrxR1. In particular, the residues Arg235, Tyr221, Gly223, Asn254 important for the ligand binding and the plasticity of the site are substituted by Ser231, Ile217, His219, Gln250 in hGR and Ala233, Val220, Ser222, Val252 in TrxTR1, respectively (Figs 9C and S7).

While testing of this compound class on other human NADPH dependent enzymes will be necessary, the initial observation that compound 3 is selective for TR with respect to hGR, together with the unique nature of the its TR binding site, allows us to speculate that NADPH competition for human NADPH binding proteins ought not be an issue for this compound class. Finally, compound 3 showed a dose-dependent anti-proliferative effect on L. infantum promastigotes at micromolar concentrations suggesting that the compound is indeed able to reach its target at the parasite levels.

Although we expect that at these mid to high concentrations there may be more than one phenomenon contributing to the anti-proliferative effect of compound 3, based on the presented data, TR inhibition is likely to be one major contributor.

Supporting information

S1 Table. Biological data for (active) follow-up compounds from class i) that are structurally related to compound 3.

S1 Fig. NADPH-Glo time course for signal stability determination. The stability of the NADPH-Glo signal was verified in the absence or presence of TR (100 pM) for 60 min. The TS2 concentration was 15 μM while the NADPH concentration was 12.5 μM. The results are reported as fold increase with respect to time 5 minutes (i.e. the shortest time possible at which the detection was made). The luminescence signal reaches its steady state after 30 minutes incubation at RT in agreement with the NADPH-Glo manual.
S2 Fig. Reducing substances interference with the NADPH-Glo signal. The effect of reducing agents (DTT and GSH) on the luminescence output of the NADPH-Glo reaction was determined in presence of NADPH concentrations from 3.12 to 50 μM. The signal was detected after 30 minutes at RT. Results are reported as fold variation with respect to the buffer (no reducing agents) control.

S3 Fig. Auranofin interference with DTNB assay. A serial dilution of AF was incubated with TR before (solid circle) and after (open circle) the TR reaction took place. The signal was then developed by the addition of DTNB and normalized between the no-TR (100%) and DMSO (0%) signals. The addition of AF, after the TR reaction was stopped (open circles and fitting), resulted in a dose-dependent decrease of the signal, suggesting that AF at least partially captures the produced T(SH)₂, thus interfering with the DTNB detection.

S4 Fig. ¹H NMR spectrum for compound 3.

S5 Fig. Compound 3 inhibition curve as determined by DTNB assay and luminescence-based assay.

S6 Fig. Superimposition between compound 3-TR complex (in magenta), TR in oxidized state (PDB code: 2JK6) (in blue) and TR in reduced state complexed with NADPH (PDB code: 2W0H). The two Arginine residues (Arg222 and Arg228) involved in the ligand binding are indicated and depicted as sticks. The picture was obtained using PyMOL (The PyMOL Molecular Graphics System, Version 2.0 Schrödinger, LLC.).

S7 Fig. Superimposition between compound 3-TR complex (in magenta) and human Thioredoxin reductase 1 (hTrxR1) (in green) (PDB code: 2CFY). The residues involved in the ligand binding are indicated (the residues of the compound 3-TR complex on the left side and the residues of human TrxR1 on the right side) and depicted as sticks. The picture was obtained using PyMOL (The PyMOL Molecular Graphics System, Version 2.0 Schrödinger, LLC.).

Acknowledgments
We acknowledge the European Synchrotron Radiation Facility (ESRF) for provision of synchrotron radiation facilities at the beamline ID29.

PDB code
The X-ray structure has been deposited in the protein data bank with the PDB (Protein Data Bank) code 6ER5.

Author Contributions
Conceptualization: Alberto Bresciani, Gianni Colotti, Andrea Ilari.
Data curation: Lorenzo Turcano, Esther Torrente, Antonino Missineo, Matteo Andreini, Marina Gramiccia, Trentina Di Muccio, Ilaria Genovese, Annarita Fiorillo, Steven Harper, Gianni Colotti, Andrea Ilari.

Funding acquisition: Alberto Bresciani, Gianni Colotti, Andrea Ilari.

Investigation: Lorenzo Turcano, Esther Torrente, Antonino Missineo, Matteo Andreini, Marina Gramiccia, Trentina Di Muccio, Ilaria Genovese, Annarita Fiorillo, Steven Harper, Alberto Bresciani, Gianni Colotti, Andrea Ilari.

Methodology: Lorenzo Turcano, Matteo Andreini, Alberto Bresciani.

Supervision: Andrea Ilari.

Writing – original draft: Lorenzo Turcano, Steven Harper, Alberto Bresciani, Gianni Colotti, Andrea Ilari.

Writing – review & editing: Steven Harper, Alberto Bresciani, Gianni Colotti, Andrea Ilari.

References

1. Desjeux P. Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis. 2004; 27(5):305–18. https://doi.org/10.1016/j.cimid.2004.03.004 PMID: 15225981.

2. Hotez PJ, Savioli L, Fenwick A. Neglected tropical diseases of the Middle East and North Africa: review of their prevalence, distribution, and opportunities for control. PLoS neglected tropical diseases. 2012; 6(2):e1475. https://doi.org/10.1371/journal.pntd.0001475 PMID: 22389729; PubMed Central PMCID: PMCPMC3289601.

3. Moore EM, Lockwood DN. Treatment of visceral leishmaniasis. J Glob Infect Dis. 2010; 2(2):151–8. https://doi.org/10.4103/0974-777X.62883 PMID: 20606971; PubMed Central PMCID: PMCPMC2889655.

4. Zulfiqar B, Shepber TB, Avery VM. Leishmaniasis drug discovery: recent progress and challenges in assay development. Drug discovery today. 2017; 22(10):1516–31. https://doi.org/10.1016/j.drudis.2017.06.004 PMID: 28647378.

5. Colotti G, Baiocco P, Fiorillo A, Boffi A, Poser E, Chiaro FD, et al. Structural insights into the enzymes of the trypanothione pathway: targets for antileishmaniasis drugs. Future medicinal chemistry. 2013; 5(15):1861–75. https://doi.org/10.4155/fmc.13.146 PMID: 24144416.

6. Fiorillo A, Colotti G, Boffi A, Baiocco P, Ilari A. The crystal structures of the tryparedoxin-tryparedoxin peroxidase couple unveil the structural determinants of Leishmania detoxification pathway. PLoS neglected tropical diseases. 2012; 6(8):e1781. https://doi.org/10.1371/journal.pntd.0001781 PMID: 22928053; PubMed Central PMCID: PMCPMC3424247.

7. Brindisi M, Brogi S, Relitti N, Vallone A, Butini S, Gemma S, et al. Structure-based discovery of the first non-covalent inhibitors of Leishmania major tryparedoxin peroxidase by high throughput docking. Scientific reports. 2015; 5:9705. https://doi.org/10.1038/srep09705 PMID: 25951439; PubMed Central PMCID: PMC4423475.

8. Dumas C, Ouellette M, Tovar J, Cunningham ML, Fairlamb AH, Tamar S, et al. Disruption of the trypanothione reductase gene of Leishmania decreases its ability to survive oxidative stress in macrophages. The EMBO journal. 1997; 16(10):2590–8. https://doi.org/10.1093/emboj/16.10.2590 PMID: 9184206; PubMed Central PMCID: PMCPMC1169870.

9. Baiocco P, Colotti G, Franceschini S, Ilari A. Molecular basis of antimony treatment in leishmaniasis. Journal of medicinal chemistry. 2009; 52(8):2603–12. https://doi.org/10.1021/jm900185q PMID: 19317451.

10. Bailey S, Smith K, Fairlamb AH, Hunter WN. Substrate interactions between trypanothione reductase and N1-glutathionylspermidine disulphide at 0.28-nm resolution. European journal of biochemistry / FEBS. 1993; 213(1):67–75. PMID: 8477734.

11. Patterson S, Alpehay MS, Jones DC, Shank's EJ, Street IP, Frearson JA, et al. Dihydroquinazolines as a novel class of Trypanosoma brucei trypanothione reductase inhibitors: discovery, synthesis, and characterization of their binding mode by protein crystallography. Journal of medicinal chemistry. 2011; 54(19):6514–30. https://doi.org/10.1021/jm200312v PMID: 21851087; PubMed Central PMCID: PMCPMC3188286.
Stump B, Eberle C, Kaiser M, Brun R, Krauth-Siegel RL, Diederich F. Diaryl sulfide-based inhibitors of trypanothione reductase inhibitors of trypanothione reductase. 2018; 8(10):1634–7. https://doi.org/10.1002/cmdc.201300276 PMID: 24039168.

15. Ilari A, Baiocco P, Messori L, Fiorillo A, Boffi A, Gramiccia M, et al. A gold-containing drug against parasitic polyamine metabolism: the X-ray structure of trypanothione reductase from Leishmania infantum in complex with auranofin reveals a dual mechanism of enzyme inhibition. Amino acids. 2012; 42(2–3):803–11. https://doi.org/10.1007/s00726-011-0997-3 PMID: 21833767; PubMed Central PMCID: PMCPMC4017975.

16. Colotti G, Ilari A, Fiorillo A, Baiocco P, Cinelli MA, Maiore L, et al. Metal-based compounds as prospective antileishmanial agents: inhibition of trypanothione reductase by selected gold complexes. ChemMedChem. 2013; 8(10):1634–7. https://doi.org/10.1002/cmdc.201300276 PMID: 24039168.

17. Colotti G, Fiorillo A, Ilari A. Metal- and metalloid-containing drugs for the treatment of trypanosomotic diseases. Front Biosci (Landmark Ed). 2018; 23:954–66. PMID: 28930584.

18. Saccolliti F, Angiulli G, Pupo G, Pescatori L, Madia VN, Messore A, et al. Inhibition of Leishmania infantum trypanothione reductase by diaryl sulfide derivatives. Journal of enzyme inhibition and medicinal chemistry. 2017; 32(1):304–10. https://doi.org/10.1080/14756366.2016.1250755 PMID: 28098499.

19. Stump B, Eberle C, Kaiser M, Brun R, Krauth-Siegel RL, Diederich F. Diaryl sulfide-based inhibitors of trypanothione reductase: inhibition potency, revised binding mode and antiparasitological activities. Organic & biomolecular chemistry. 2008; 6(21):3933–47. https://doi.org/10.1039/b806371k PMID: 18931800.

20. Holloway GA, Baell JB, Fairlamb AH, Novello PM, Parissot JP, Richardson J, et al. Discovery of 2-imino-benzimidazoles as a new class of trypanothione reductase inhibitor by high-throughput screening. Bioorganic & medicinal chemistry letters. 2007; 17(5):1422–7. https://doi.org/10.1016/j.bmcl.2006.11.090 PMID: 17194585; PubMed Central PMCID: PMCPMC3428904.

21. Dixon MJ, Maurer RI, Biggi C, Oyarzabal J, Essex JW, Bradley M. Mechanism and structure-activity relationships of norspermidine-based peptidic inhibitors of trypanothione reductase. Bioorganic & medicinal chemistry. 2005; 13(14):4513–26. https://doi.org/10.1016/j.bmc.2005.04.039 PMID: 15922604.

22. Spinks D, Shanks EJ, Cleghorn LA, McElroy S, Jones D, James D, et al. Investigation of trypanothione reductase as a drug target in Trypanosoma brucei. ChemMedChem. 2009; 4(12):2060–9. https://doi.org/10.1002/cmdc.200900262 PMID: 19924760; PubMed Central PMCID: PMC2855869.

23. Baiocco P, Poce G, Alfonso S, Cocozza M, Porretta GC, Colotti G, et al. Inhibition of Leishmania infantum trypanothione reductase by azole-based compounds: a comparative analysis with its physiological substrate by X-ray crystallography. ChemMedChem. 2013; 8(7):1175–83. https://doi.org/10.1002/cmdc.201300176 PMID: 23733388.

24. Hamilton CJ, Saravanamuthu A, Poupot C, Fairlamb AH, Eggleston IM. Time-dependent inhibitors of trypanothione reductase: analogues of the spermidine alkaloid lunarine and related natural products. Bioorganic & medicinal chemistry. 2006; 14(7):2266–78. https://doi.org/10.1016/j.bmc.2005.11.004 PMID: 16303308.

25. Martyn DC, Jones DC, Fairlamb AH, Clardy J. High-throughput screening affords novel and selective trypanothione reductase inhibitors with anti-trypanosomal activity. Bioorganic & medicinal chemistry letters. 2007; 17(5):1280–3. https://doi.org/10.1016/j.bmcl.2006.12.016 PMID: 17197182; PubMed Central PMCID: PMCPMC438910.

26. Hamilton CJ, Saravanamuthu A, Eggleston IM, Fairlamb AH. Ellman's reagent-mediated inhibition of trypanothione reductase. The Biochemical journal. 2003; 369(Pt 3):529–37. https://doi.org/10.1042/BJ20021298 PMID: 12416994; PubMed Central PMCID: PMCPMC1223126.

27. Rogers DJ, Tanimoto TT. A Computer Program for Classifying Plants. Science. 1960; 132(3434):1115–8. https://doi.org/10.1126/science.132.3434.1115 PMID: 17790723.

28. Baiocco P, Franceschini S, Ilari A, Colotti G. Trypanothione reductase from Leishmania infantum: cloning, expression, purification, crystallization and preliminary X-ray data analysis. Protein and peptide letters. 2009; 16(2):196–200. PMID: 19200044.
29. Butina D. Unsupervised Data Base Clustering Based on Daylight’s Fingerprint and Tanimoto Similarity: A Fast and Automated Way To Cluster Small and Large Data Sets. J Chem Inf Comput Sci. 1999; 39 (4):4. https://doi.org/10.1021/ci9803381

30. Xds Kabsch W. Acta crystallographica Section D, Biological crystallography. 2010; 66(Pt 2):125–32. https://doi.org/10.1107/S0907444909047337 PMID: 20124692; PubMed Central PMCID: PMCPMC2815665.

31. Vagin A, Teplyakov A. Molecular replacement with MOLREP. Acta crystallographica Section D, Biological crystallography. 2010; 66(Pt 1):22–5. https://doi.org/10.1107/S0907444909042589 PMID: 20057045.

32. Murshudov GN, Vagin AA, Dodson EJ. Refinement of macromolecular structures by the maximum-likelihood method. Acta crystallographica Section D, Biological crystallography. 1997; 53( Pt 3):240–55. https://doi.org/10.1107/S0907444996012255 PMID: 15299926.

33. Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta crystallographica Section D, Biological crystallography. 2004; 60(Pt 12 Pt 1):2126–32. https://doi.org/10.1107/S0907444904019158 PMID: 15572765.

34. Sereno D, Lemesre JL. Use of an enzymatic micromethod to quantify amastigote stage of Leishmania amazonensis in vitro. Parasitol Res. 1997; 83(4):401–3. PMID: 9134568.

35. Angiulli G, Lantella A, Forte E, Angelucci F, Colotti G, Ilari A, et al. Leishmania infantum trypanothione reductase is a promiscuous enzyme carrying an NADPH:O2 oxidoreductase activity shared by glutathione reductase. Biochimica et biophysica acta. 2015; 1850(9):1891–7. https://doi.org/10.1016/j.bbagen.2015.05.022 PMID: 26033467.

36. Albert A, Brauckmann C, Blaske F, Sperling M, Engelhard C, Karst U. Speciation analysis of the anti-rheumatic agent Auranofin and its thiol adducts by LC/ESI-MS and LC/ICP-MS. J Anal Atom Spectrom. 2012; 27(6):975–81. https://doi.org/10.1039/c2ja30109a WOS:000304095300008.

37. Zhang JH, Chung TD, Oldenburg KR. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen. 1999; 4(2):67–73. https://doi.org/10.1177/108705719900400206 PMID: 10838414.

38. Persch E, Bryson S, Todoroff NK, Eberle C, Thelemann J, Dirdjaja N, et al. Binding to large enzyme pockets: small-molecule inhibitors of trypanothione reductase. ChemMedChem. 2014; 9(8):1880–91. https://doi.org/10.1002/cmdc.201402032 PMID: 24788386.